Suchen
Forte Biosciences Inc
FBRXZur Watchlist hinzufügen
20.920USD
-0.400-1.88%
Handelsschluss 07/02, 13:00（ET）Kurse um 15 Minuten verzögert
270.88MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Forte Biosciences Inc Unternehmen
Forte Biosciences, Inc. is a clinical-stage biopharmaceutical company that is advancing FB102, which is an anti-CD122 monoclonal antibody therapeutic candidate with potentially broad autoimmune and autoimmune-related indications. It is advancing clinical development of FB102 into patient-based trials for celiac disease and non-segmental vitiligo. The Company's FB102 program focuses on addressing key pathways implicated in these indications with a CD122 antagonist. CD122 is a subunit of IL-2/IL-15 receptors which are key regulators of NK cells and certain T cell subsets. FB102 has potentially other autoimmune and autoimmune-related applications including vitiligo, alopecia areata, and type 1 diabetes (T1D). Its subsidiaries include Forte Subsidiary, Inc. and Forte Biosciences Australia Proprietary Limited.
Forte Biosciences Inc Informationen
BörsenkürzelFBRX
Name des UnternehmensForte Biosciences Inc
IPO-datumApr 13, 2017
CEOWagner (Paul A)
Anzahl der mitarbeiter14
WertpapierartOrdinary Share
GeschäftsjahresendeApr 13
Addresse3060 Pegasus Park Drive
StadtDALLAS
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl75247
Telefon13106186994
Websitehttps://www.fortebiorx.com/home/default.aspx
BörsenkürzelFBRX
IPO-datumApr 13, 2017
CEOWagner (Paul A)
Führungskräfte von Forte Biosciences Inc
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Paul A. Wagner, Ph.D.
Dr. Paul A. Wagner, Ph.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
84.33K
+1.37%
Mr. Antony A. Riley
Mr. Antony A. Riley
Chief Financial Officer
Chief Financial Officer
41.98K
+0.91%
Mr. David W. (Dave) Gryska
Mr. David W. (Dave) Gryska
Independent Director
Independent Director
5.94K
--
Mr. Steven Kornfeld
Mr. Steven Kornfeld
Independent Director
Independent Director
3.96K
--
Dr. Stephen K. Doberstein, Ph.D.
Dr. Stephen K. Doberstein, Ph.D.
Independent Director
Independent Director
--
--
Dr. Barbara K. Finck, M.D.
Dr. Barbara K. Finck, M.D.
Director, Senior Medical Clinician
Director, Senior Medical Clinician
--
--
Dr. Scott C. Brun, M.D.
Dr. Scott C. Brun, M.D.
Independent Director
Independent Director
--
--
Mr. Richard G. (Rich) Vincent, CPA
Mr. Richard G. (Rich) Vincent, CPA
Independent Director
Independent Director
--
--
Mr. Shiv Kapoor
Mr. Shiv Kapoor
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Paul A. Wagner, Ph.D.
Dr. Paul A. Wagner, Ph.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
84.33K
+1.37%
Mr. Antony A. Riley
Mr. Antony A. Riley
Chief Financial Officer
Chief Financial Officer
41.98K
+0.91%
Mr. David W. (Dave) Gryska
Mr. David W. (Dave) Gryska
Independent Director
Independent Director
5.94K
--
Mr. Steven Kornfeld
Mr. Steven Kornfeld
Independent Director
Independent Director
3.96K
--
Dr. Stephen K. Doberstein, Ph.D.
Dr. Stephen K. Doberstein, Ph.D.
Independent Director
Independent Director
--
--
Dr. Barbara K. Finck, M.D.
Dr. Barbara K. Finck, M.D.
Director, Senior Medical Clinician
Director, Senior Medical Clinician
--
--
Häufig gestellte Fragen
Wer sind die fünf größten Anteilseigner von Forte Biosciences Inc?
Die fünf größten Anteilseigner von Forte Biosciences Inc sind: Dr. Paul A. Wagner, Ph.D.
Wie viele Institutionen halten Anteile an Forte Biosciences Inc (FBRX)?
Mit Stand vom 2026Q1 halten 108 Institutionen Anteile an Forte Biosciences Inc, mit einem Gesamtmarktwert von etwa 12.72M, was 65.47% der Gesamtanteile entspricht. Im Vergleich zum 2025Q4 ist der institutionelle Aktienbesitz um 288877.00 gestiegen.